This episode of ChaiTime featured four o2h-backed exciting human health companies, all of which are considering a Seed Plus or Series A funding round in the near future.
Moderated by Andy Richards, a well-known Investor and Entrepreneur who requires very little introduction in the UK biotech community, the panel featured an AI driven drug discovery company, a stem cell liver on-a-chip platform, a biotech focused on known recreational drugs for treatment of depression, and a company developing faster acting Insulin.
Ruchi is developing an organ-on-chip platform which integrates stem cell research and tissue engineering to provide alternatives to cancer lines and animal models for drug toxicity screening.
Peter is both a passionate chemist and a trained patent attorney. They have a stealth program that is progressing toward the clinic which uses a known active recreational drug to treat mental health conditions.
Sarah has made significant strides in building Arecor into a global leader focused on advancing today’s therapies to enable healthier lives.
Szabi has placed Turbine firmly on the map as one of the global leaders in the intersection of AI and pharmaceutical new drug discovery.
Andy Richards is an entrepreneur and investor. He is been involved in many of the success stories that have come out of Cambridge.